Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -
Authors:
- Masatsugu HoriMHMasatsugu Hori
- the RE-LY InvestigatorsTIthe RE-LY Investigators
- 1 January 2011
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 75 (4) , 800-805
Abstract
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societiesKeywords
This publication has 14 references indexed in Scilit:
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAmerican Heart Journal, 2009
- Complications in the Catheter Ablation of Atrial FibrillationCirculation Journal, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksCochrane Database of Systematic Reviews, 2007
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysisThrombosis Research, 2006
- Oral Anticoagulants vs Aspirin in Nonvalvular Atrial FibrillationJAMA, 2002
- Optimal Intensity of International Normalized Ratio in Warfarin Therapy for Secondary Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation.Internal Medicine, 2001